ITOC 2020 | HDACi and IL21: reprogramming CD8+ T-cells to memory T-cells

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the in vitro generation of highly persistent T-cell populations using histone deacetylase inhibitor (HDACi) and IL21 to reprogram differentiated human CD8+ T-cells into central memory–like T-cells. This can augment the efficacy of adoptively transferred T-cells as there is a correlation with clinical response rates in adoptive cell therapy (ACT). This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.